Occurrence of colon ischemia in relation to irritable bowel syndrome.
about
Migraine, fibromyalgia, and depression among people with IBS: a prevalence studyThe utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study.Incidence of ischemic colitis in treated, commercially insured hypertensive adults: a cohort study of US health claims data.Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.Dissecting oesophageal sensori-motor functions: the fourth domain.CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection.An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DIschemic colitis after mesotherapy combined with anti-obesity medications.Factors predicting poor prognosis in ischemic colitis.Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.Predictors of mortality among patients undergoing colectomy for ischemic colitis: A population-based United States study.A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis.Review of tegaserod in the treatment of irritable bowel syndrome.Targeted therapies for diarrhea-predominant irritable bowel syndrome.Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.Tegaserod-associated ischemic colitis.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation.Ischemic colitis and large bowel infarction: a case reportThe rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.Histopathological alterations in irritable bowel syndrome.Pharmacologically mediated colon ischemia.A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome.Systematic review on the treatment of ischaemic colitis.The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.A review of ischemic colitis: is our clinical recognition and management adequate?5-HT7 receptor signaling: improved therapeutic strategy in gut disordersUpdate on Colon Ischemia: Recent Insights and Advances.Update on the Diagnosis and Management of Colon Ischemia.A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.Efficacy of tegaserod in chronic constipation in men.The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine.Hyperamylasaemia and ischaemic colitis.Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Tegaserod in the treatment of irritable bowel syndrome with constipation.Mast cells drive mesenteric afferent signalling during acute intestinal ischaemia.
P2860
Q24672013-9202C97C-B1FC-4CF4-AE54-DE88E1A8CB00Q30574620-A294919B-440A-4908-9E49-CC2732B67419Q30882778-0AED1ADA-F69D-4950-A29F-49CF4358C8A8Q31036400-3999A1CB-1EE6-4551-BE32-5BFA7C7DB36CQ33234279-6B71C3D7-FEC4-469A-BDA1-28694BBE8B6FQ33274027-CEF8B705-3141-4565-B147-40052E055AB7Q33667183-9673FF79-375E-4B29-A808-A4AB00816DDCQ33756309-A6E529EC-57F1-45C5-A842-AF9A5A42CABBQ33867035-5A4E904F-F96E-488E-90F5-5D4AC5D40890Q34409173-A99AF098-8D04-4BBB-A10E-E16AA942DBA7Q34849102-11572DA5-A07D-41B5-ACEA-59191388B7D4Q35079637-5C79751B-9DDA-412F-BD00-6BB2A5D58FCAQ35925555-6EB2BE9C-1CF7-47CA-AA5A-FA1557454B46Q36065945-3CDD4E96-CA0A-4A50-BAF5-36706B30D173Q36065990-24F299A0-107B-465B-AFA8-F8AA90451935Q36072690-F6689036-167D-4E96-AA47-D61120451E81Q36174477-574FE981-F210-49EA-AFDA-03A8074A04A2Q36297736-3404AFFC-A819-47E6-B61F-D2295A83B120Q36321320-E8A7F1ED-5312-4A20-BEBA-D69622D00E65Q36351947-CF11D5D4-7AE3-4195-91BB-792D896D1C5EQ36407290-45B2B1BD-92B7-4599-809D-A2138CF928DFQ36609410-7A0D68C4-8278-4A69-8D52-46D1A84154E5Q36815199-D02AE340-3481-4742-AE0B-7849342FB255Q37130608-F91F6D96-8773-4E7F-AD02-6FF7051B1757Q37346021-0EA8EC92-93A7-4D84-82C5-F8812423017FQ37608344-47F887A4-6165-407C-90B4-B215560A9293Q37726109-54173F94-283E-4677-8685-4473BA5CA71FQ37887773-8465BC5E-0F52-4A8A-A0D9-9E7B2A4BFC07Q38144152-33E32D2A-49DD-44B0-A256-33C9BD2309FEQ38310117-6D8C04DE-F51E-41EC-86A3-5D1CA64F5032Q38601832-6F04917D-7E5D-4195-A0B0-21F3BE8ECA3BQ38713080-BFE78558-9E91-476B-9A1D-F5D51AF1F5D3Q39335358-327C076A-F215-474E-8D6D-CEFAC7F89113Q39342577-A45F17FA-8054-4189-898B-06FFAE23D52CQ39372818-A6921E0F-A1A3-4846-979E-BAFFBDFD4006Q41948539-F91ECF9D-8C96-406D-BCCD-F9C2E1C47287Q43144574-C23F6EE0-C86A-41B8-BAB8-8405F72A9EBCQ43171523-E7A86C90-6A9C-4160-9C12-76BCD2F7C6D6Q43267055-D52669E9-7EA9-4241-A17F-2BB96BDCD08EQ43438704-210999D5-0887-4E02-AAC3-59E713B57F22
P2860
Occurrence of colon ischemia in relation to irritable bowel syndrome.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Occurrence of colon ischemia in relation to irritable bowel syndrome.
@en
type
label
Occurrence of colon ischemia in relation to irritable bowel syndrome.
@en
prefLabel
Occurrence of colon ischemia in relation to irritable bowel syndrome.
@en
P2093
P2860
P1476
Occurrence of colon ischemia in relation to irritable bowel syndrome.
@en
P2093
Alexander M Walker
Anuli N Ajene
Bruce E Sands
David P Miller
J Alexander Cole
Suzanne F Cook
P2860
P304
P356
10.1111/J.1572-0241.2004.04097.X
P407
P577
2004-03-01T00:00:00Z